BeyondSpring Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $1.8 million compared to $1.9 million in the prior year period. Research and development expenses remained flat at $1.0 million, while general and administrative expenses decreased by $0.1 million to $0.8 million due to lower legal and consulting costs. Cash, cash equivalents, and short-term investments declined to $6.5 million from $12.6 million as of December 31, 2025. The company highlighted clinical data for Plinabulin presented at ASCO 2026 and AACR 2026, supporting its confirmatory Phase 3 DUBLIN-4 study in non-squamous NSCLC. Additionally, BeyondSpring announced a leadership transition effective July 1, 2026, appointing Min Qiu as CEO, Dr. Jiangwen (Jen) Majeti as Vice Chairman, and Na Li as CFO to focus on advancing the DUBLIN-4 program. BeyondSpring Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer.

BeyondSpring Inc. finalized the compensatory arrangements for newly appointed Chief Executive Officer Min Qiu, providing an annual salary of $100,000 and a target annual bonus of 30% of base salary. The agreement includes a grant of 100,000 ordinary shares via options that vest in four equal annual installments. BeyondSpring Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions.